ACE inhibition in hypertension: Focus on perindopril

American Journal of Cardiovascular Drugs

Volumn 7, Issue 5, 2007, Pages 303-317

  Cockcroft, John R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

ACE inhibitors, pharmacodynamics; ACE inhibitors, therapeutic use; Hypertension, treatment; Perindopril, therapeutic use

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; NEBIVOLOL; NIFEDIPINE; PERINDOPRIL; PERINDOPRILAT; QUINAPRIL; RAMIPRIL; RESERPINE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTERY COMPLIANCE; ATHEROSCLEROSIS; BINDING AFFINITY; CLINICAL PROTOCOL; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY COUGH; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 35449002500     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707050-00001     Document Type: Review

References (100)

1. Staessen JA, Birkenhager WH. Evidence that new antihypertensives are superior to older drugs. Lancet 2005; 366 (9489): 869-71
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-72
4. Strauss MH, Lonn EM, Verma S. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. Eur Heart J 2005; 26 (22): 2351-3
5. Verdecchia P, Angeli F, Gattobigio R, et al. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26 (22): 2381-6
6. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004; 329 (7477): 1248-9
7. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25 (5): 951-8
8. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362 (9395): 1527-35
9. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906
10. Poulter NR, Sever PS. Anglo-Scandinavian Cardiac Outcomes Trial: history, results and implications for the management of high blood pressure. Birmingham, UK: Sherborne Gibbs Ltd, 2005
11. National Institute for Health and Clinical Excellence (NICE). NICE guideline: draft for consultation. Hypertension: management of hypertension in adults in primary care (partial update), London, 2006 [online]. Available from URL: http://www.nice.org.uk/pdf/Hypertension_update_NICE_0206.pdf [Accessed 2007 Sep 20]
12. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105-87
13. Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002; 16 (2): 149-60
14. Prescribing information Mavik® (trandolapril tablets). Abbott Laboratories. [on line]. Available from URL: http://www.rxabbott.com/pdf/mavik. pdf [Accessed 2007 Aug 3]
15. Prescribing Information Zestril® (lisinopril). AstraZeneca. [online]. Available from URL: http://www.astrazeneca-us.com/pi/zestrillpv.pdf [Accessed 2007 Aug 3]
16. Prescribing information Monopril® (fosinopril sodium tablets). Bristol-Myers Squibb Company. [online]. Available from URL: http://www.fda.gov/ cder/foi/lavel/2003/199115se5-037_monopril_1b1.pdf. [Accessed 2007Aug 3]
17. Prescribing information Vasotec® (enalapril maleate). Food and Drug Administration. [online]. Available from URL: http://www.fda.gov/cder/pediatric/ lavels/Enalapri.PDF [Accessed 2007 Aug 3]
18. Prescribing information Altace® tablets (ramipril). Food and Drug Administration. [online]. Available from URL: http://www.fda.gov/cder/foi/label/ 2007/0220211b1.pdf [Accessed 2007 Aug 3]
19. Prescribing information Aceon® (perindopril erbumine) tablets). Food and Drug Administration. [online]. Available from URL: http://www.fda.gov/cder/ foi/label/2005/020184s0111b1.pdf [Accessed 2007 Aug 3]
20. Prescribing information Accupril® (quinapril hydrochloride tablets). Pfizer. [online]. Available from URL: http://www.pfizer.com/pfizer/download/ uspi_accupril.pdf [Accessed 2007 Aug 3]
21. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005; 3 (1): 15-29
22. Louis WJ, Conway EL, Krum H, et al. Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril. Clin Exp Pharmacol Physiol Suppl 1992; 19: 55-60
23. Johnston CI, Fabris B, Yamada H, et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989; 7 (5): S11-6
24. Louis WJ, Workman BS, Conway EL, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. J Cardiovasc Pharmacol 1992; 20 (3): 505-11
25. Squire IB, MacFayden RJ, Reid JL, et al. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin- converting enzyme inhibitors in congestive heart failure. J Cardiovasc Pharmacol 1996; 27 (5): 657-66
26. Julius S, Cohn JN, Neutel J, et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens (Greenwich) 2004; 6 (1): 10-7
27. Chrysant SG, McDonald RH, Wright JT, et al. Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. The Perindopril Study Group. Clin Pharmacol Ther 1993; 53 (4): 479-84
28. Su JB, Barbe F, Crozatier B, et al. Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure. J Cardiovasc Pharmacol 1999; 34 (5): 700-10
29. Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39 (2 Pt 2): 634-8
30. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial function: results of a substudy of the EUROPA study - PERTINENT. Cardiovasc Res 2007; 73 (1): 237-46
31. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340 (2): 115-26
32. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91 (11): 2844-50
33. Vaughan DE, Rouleau JL, Ridker PM, et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: HEART Study Investigators. Circulation 1997; 96 (2): 442-7
34. Shibutani T, Kanda A, Ishigai Y, et al. Inhibitory effect of perindopril, a novel angiotensin-converting enzyme inhibitor, on neointima formation after balloon injury in rats and cholesterol-fed rabbits. J Cardiovasc Pharmacol 1994; 24 (3): 509-16
35. Wong J, Rauhoft C, Dilley RJ, et al. Angiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formation. Circulation 1997; 96 (5): 1631-40
36. Kishi Y, Ohta S, Kasuya N, et al. Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells. J Hypertens 2003; 21 (7): 1347-53
37. Okrucka A, Pechan J, Kratochvilova H. Effects of the angiotensin- converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension. Platelets 1998; 9 (1): 63-7
38. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15 (4 Pt 1): 316-20
39. Matsumoto T, Minai K, Horie H, et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003; 41 (8): 1373-9
40. Candido R, Jandeleit-Dahm KA, Cao Z, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002; 106 (2): 246-53
41. Van Belle E, Meurice T, Tio FO, et al. ACE inhibition accelerates endothelial regrowth in vivo: a possible explanation for the benefit observed with ACE inhibitors following arterial injury. Biochem Biophys Res Commun 1997; 231 (3): 577-81
42. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41 (6): 1281-6
43. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94 (3): 258-65
44. Gomma A, Henderson J, Purcell H, et al. The clinical application of ACE inhibitors in coronary artery disease. Br J Cardiol 2002; 9: 158-62
45. Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005; 23 (1): S27-33
46. Mathiassen ON, Buus NH, Sihm I, et al. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 2007; 25 (5): 1021-6
47. Rizzoni D, Palombo C, Porteri E, et al. Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients. J Hypertens 2003; 21 (3): 625-31
48. Agabiti-Rosei E, Ambrosioni E, Finardi G, et al. Perindopril versus captopril: efficacy and acceptability in an Italian multicenter trial. Am J Med 1992; 92 (4B): 79S-83S
49. Buus NH, Bottcher M, Jorgensen CG, et al. Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension 2004; 44 (4): 465-70
50. Grandi AM, Bignotti M, Gaudio G, et al. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. J Cardiovasc Pharmacol 1995; 26 (5): 737-41
51. Grandi AM, Venco A, Barzizza F, et al. Double-blind comparison of perindopril and captopril in hypertension. Effects on left ventricular morphology and function. Am J Hypertens 1991; 4 (6): 516-20
52. Hui Y, Dai Z, Chen X, et al. Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension. Chin Med J (Engl) 1995; 108 (9): 678-81
53. Kuperstein R, Sasson Z. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: a randomized, double-blind, controlled study of 21 obese hypertensives. Circulation 2000; 102 (15): 1802-6
54. Effects of enalapril on left ventricular function and exercise performance after a first acute myocardial infarction: the EDEN Study Investigators. Int J Cardiol 1997; 59 (3): 257-65
55. Baur LH, Schipperheyn JJ, van der Wall EE, et al. Beneficial effect of enalapril on left ventricular remodelling in patients with a severe residual stenosis after acute anterior wall infarction. Eur Heart J 1997; 18 (8): 1313-21
56. Bonarjee VV, Carstensen S, Caidahl K, et al. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy: CONSENSUS II Multi-Echo Study Group. Am J Cardiol 1993; 72 (14): 1004-9
57. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995; 91 (10): 2573-81
58. Keren G, Pardes A, Eschar Y, et al. One-year clinical and echocardiographic follow-up of patients with congestive cardiomyopathy treated with captopril compared to placebo. Isr J Med Sci 1994; 30 (1): 90-8
59. Kjoller-Hansen L, Steffensen R, Grande P. Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular function and no clinical heart failure. J Am Coll Cardiol 2001; 37 (5): 1214-20
60. Kongstad-Rasmussen O, Blomstrand P, Broqvist M, et al. Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction. Clin Cardiol 1998; 21 (11): 807-11
61. Nicolosi GL, Latini R, Marino P, et al. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Eur Heart J 1996; 17 (11): 1646-56
62. van Gilst WH, Kingma JH, Peels KH, et al. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). J Am Coll Cardiol 1996; 28 (1): 114-21
63. Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006; 166 (6): 659-66
64. Mallareddy M, Parikh CR, Peixoto AJ. Effect of angiotensin-converting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2006; 8 (6): 398-403
65. Asmar RG, Pannier B, Santoni JP, et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78 (4): 941-50
66. Kool MJ, Lustermans FA, Breed JG, et al. The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens 1995; 13 (8): 839-48
67. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48 (1): 80-6
68. Pannier B, Guerin AP, Marchais SJ, et al. Benefits from angiotensin-converting enzyme inhibition in patients with renal failure: latest results. Eur Heart J 2003; 5: E18-22
69. Asmar R, Topouchian J, Pannier B, et al. Pulse wave velocity as endpoint in large-scale intervention trial: the Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J Hypertens 2001; 19 (4): 813-8
70. Asmar RG, London GM, O'Rourke ME, et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38 (4): 922-6
71. London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90 (6): 2786-96
72. Sihm I, Schroeder AP, Aalkjaer C, et al. Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE inhibitor perindopril. Blood Press 1995; 4 (4): 241-8
73. Thybo NK, Stephens N, Cooper A, et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25 (4 Pt 1): 474-81
74. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354 (9192): 1751-6
75. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353 (9153): 611-6
76. Neaton JD, Grimm Jr RH, Prineas RJ et al. Treatment of Mild Hypertension Study. Final results: Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270 (6): 713-24
77. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST). A randomized controlled trial. JAMA 2003; 290 (21): 2805-16
78. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348 (7): 583-92
79. Guo W, Turlapaty P, Shen Y, et al. Clinical experience with perindopril in patients nonresponsive to previous antihypertensive therapy: a large US community trial. Am J Ther 2004; 11 (3): 199-205
80. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782-8
81. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351 (20): 2058-68
82. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 145-53
83. Fox KM, Bertrand ME, Remme WJ, et al. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. Am Heart J 2007; 153 (4): 629-35
84. Yusuf S, Pogue J. ACE inhibition in stable coronary artery disease. N Engl J Med 2005; 352 (9): 937-9, author reply 937-9
85. Bertrand ME, Remme WJ, Fox KM, et al. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. Int J Cardiol 2007; 121 (1): 57-61
86. Deckers JW, Goedhart DM, Boersma E, et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 2006; 27 (7): 796-801
87. McCullough C. ACE inhibition in stable coronary artery disease. N Engl J Med 2005; 352 (9): 937-9, author reply 937-9
88. Myers MG. ACE inhibition in stable coronary artery disease. N Engl J Med 2005; 352 (9): 937-9, author reply 937-9
89. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113 (9): 1213-25
90. Pilote L, Abrahamowicz M, Rodrigues E, et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141 (2): 102-12
91. Jansen PA, De Vries OO, De Rooy SE, et al. Blood pressure reduction after the first dose of captopril and perindopril. J Am Geriatr Soc 2001; 49 (11): 1574-5
92. Lau CP, Tse HF, Ng W, et al. Comparison of perindopril versus captopril for treatment of acute myocardial infarction. Am J Cardiol 2002; 89 (2): 150-4
93. Reid JL, MacFadyen RJ, Squire IB, et al. Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose. Am Heart J 1993; 126 (3 Pt 2): 794-7
94. Vitovec J, Spinar J. First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril: Slovak Investigator Group. Eur J Heart Fail 2000; 2 (3): 299-304
95. Dart AM, Cameron JD, Gatzka CD, et al. Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial. Hypertension 2007; 49 (6): 1242-7
96. Daly CA, Fox KM, Remme WJ, et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26 (14): 1369-78
97. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370 (9590): 829-40
98. Poggi L, Renucci JF, Denolle T. Treatment of essential hypertension in general practice: an open-label study of 47,351 French hypertensive patients treated for one year with perindopril. Can J Cardiol 1994; 10 Suppl. D: 21D-4D
99. Clark LT. Safety profile of perindopril. Am J Cardiol 2001; 88 (7A): 36i-40i
100. Beltrami L, Zingale LC, Carugo S, et al. Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opin Drug Saf 2006; 5 (5): 643-9